Innovation Science
The company is a drug research and development organization that promotes interdisciplinary collaboration across a wide range of expertises. The core technical members possess over two decades of experience in innovative drug research and development; including but not limited to expertise in core technologies for the research and development of a novel class of targeted therapies, as well as comprehensive capabilities in designing and implementing the entire chain of new drug development. Our product development spans across all stages, from early discovery to late-stage development, including target identification and mechanism validation for innovative drugs, molecular design and screening of compounds, preclinical research, translational scientific studies, CMC (Chemistry, Manufacturing, and Controls), design and execution of clinical protocols, and new drug registration.
1. Focused on Independent Research and Development of First-in-Class Innovative Drugs
BeBetter is a biopharmaceutical company dedicated to independent research and development of innovative drugs with a clinical value-oriented approach. The company focuses on major disease areas including oncology, autoimmune diseases, and metabolic disorders. Leveraging its proprietary core technology platform, BeBetter develops First-in-Class and innovative drugs targeting unmet clinical needs.
In 2022, the company ranked fifth nationally in the application of Class I New Drugs.
Additionally, BeBetter ranked fourth among innovative pharmaceutical companies in the field of life science in the 2022 Nature Index.
The company's R&D pipeline includes 7 independently developed core innovative drug products that are in various stages of clinical trials. Among them, BEBT-908 NDA application submitted in Sept 2023. BEBT-209 is in Phase III clinical trials, BEBT-109 Receives CDE Consent for Phase III Clinical Trial in Sept 2023, and 4 products are in Phase I clinical trials. Additionally, the company has multiple innovative drug products in the preclinical research stage.
2. Abundant pipelines
Up to this point, we have successfully established an extensive pipeline comprising 11 first-in-class new drug candidates targeting 19 indications, with a total of 33 clinical approvals.
We are currently conducting 1 pivotal Phase II trial, 1 Phase III trial, 7 Phase II trial, and 8 Phase I trials.
BEBT-908 is the world's first dual-target inhibitor of PI3K/HDAC.
Multiple products are scheduled for consecutive market releases starting from 2024.
3. Continuous Innovation to Enhance Core Competitiveness
The company continues to leverage the rich innovative drug development experience of its core management and R&D teams, progressively expanding its focus from drug research in oncology to include a wider range of major diseases, specifically large-market indications. Additionally, BeBetter will evolve its drug research capabilities to include the simultaneous development of chemical drugs and oligonucleotide drugs. This approach establishes a diverse portfolio of first-in-class innovative drug pipelines across significant disease areas such as malignant tumors, autoimmune diseases, and metabolic disorders. These efforts aim to continuously enhance the company's market position and competitiveness in the domestic and international innovative drug industry.
The company's workforce includes a number of overseas returnees, Ph.D. holders, and the R&D staff comprises 80% of the total employees.
The core team of the company has been honored with accolades such as leading technological talents in the Guangzhou Development Zone, members of the Guangdong "Pearl River Talent Plan" innovative entrepreneurship team, and leaders of entrepreneurial teams in Guangzhou.
Three major core technology platforms have been established: New Drug Discovery Platform, Anti-Tumor Drug Resistance Combination Therapy Platform, and Differentiated Clinical Design and Development Platform.
4. Global Vision Strategy
Global Patent Deployment, with 32 authorized patents (12 in Chinese mainland, 7 in Hong Kong and Taiwan, 13 in PCT national phases);
Conducting overseas clinical trials;
Initiating global pharmaceutical company collaboration and exchanges.
Publications
(underline indicates current R&D team members at the company)
1. Dual-Target Inhibitors of Protein Kinases and HDAC
Fan F, Liu P, Bao R, Chen L, Zhou M, Mo Z, Ma Y, Liu H, Zhou Y, Cai X, Qian C, Liu X. A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy, Cancer Res. 81:6233-45, 2021.
Qian C, Lai CJ, Bao R, Wang DG, Wang J, Xu GX, Atoyan R, Qu H, Yin L, Samson M, Forrester J, Zifcak B, Ma A, DellaRocca S, Borek M, Zhai HX, Cai X, Vio M. Cancer Network Disruption with a Single Molecule Targeting Histone Deacetylase Epigenatics and PI3K Pathway. Clin Cancer Res. 18: 4104-13, 2012.
Cai X, Qian C. Chapter 14 Discovery of HDAC-Inhibiting Multi-Target Inhibitors. In Designing Multi-Target Drugs. RSC Publishing Editor(s): Morphy J. R, Harris C J. 221-242.
Lai CJ, Bao R, Tao X, Wang J, Atoyan R, Qu H, Wang DG, Yin L, Samson M, Forrester J, Zifcak B, Xu GX, DellaRocca S, Zhai HX, Cai X, Munger WE, Keegan M, Pepicelli CV, Qian C. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res. 70:3647-56, 2010.
Cai X, Zhai HX, Wang J, Forrester J, Qu H, Yin L, Lai CJ, Bao R, Qian C. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N- hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J Med Chem. 53:2000-09, 2010.
2. Chaperone Inhibitors
Bao R, Lai CJ, Wang DG, Qu H, Yin L, Zifcak B, Tao X, Wang J, Atoyan R, Samson M, Forrester J, Xu GX, DellaRocca S, Borek M, Zhai HX, Cai X, Qian C. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. Mol Cancer Ther. 8:3296-06, 2009.
Bao R, Lai CJ, Qu H, Wang D, Yin L, Zifcak B, Atoyan R, Wang J, Samson M, Forrester J, DellaRocca S, Xu GX, Tao X, Zhai HX, Cai X, Qian C. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res. 15:4046-57, 2009.
3. Broad-Spectrum EGFR Mutant Inhibitors
Fan F, Zhou M, Ye X, Mo Z, Ma Y, Luo L, Liang X, Liu H, Weng W, Lin M, Liu X, Cai X, Qian. BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer. Transl Oncol 14:100961m 2021.
Copyright ©2018-2022 Guangzhou BeBetter Medicine Technology Co, LTD.粤ICP备18065301号